Release date: 2014-11-03
Scientists in Canada and the United States announced that they had developed a 100-percent Ebola vaccine in monkeys about a decade ago, but because the Ebola vaccine had no market value at the time, scientists had not conducted human trials.
The New York Times reported that as early as about a decade ago, American and Canadian scientists used another virus, the vesicular stomatitis virus (VSV), to make the Ebola vaccine. Previously, scientists have used the virus to develop other vaccines.
The scientist took out one of the genes of the vesicular stomatitis virus and implanted a gene from the Ebola virus that forces the Ebola protein to appear on the surface of the vesicular stomatitis virus. This type of protein does not induce disease, but it stimulates the immune system to function in monkeys to fight the virus.
At the time, the scientists said that human trials could be launched within two years, and at 2010 or 2011, the vaccine could be used to apply for a sales permit.
The Public Health Agency of Canada applied for a patent for the vaccine called "VSV-EBOV" and issued a production license in 2010 to NewLink Genetics. At the time, they produced about 800 to 1000 doses of the vaccine.
However, the vaccine was shelved after the vaccine. Until the recent Ebola outbreak in West Africa and nearly 5,000 lives, the Canadian government donated the vaccine to the World Health Organization and launched human clinical trials on healthy volunteers.
The development of the Ebola vaccine was stagnant at the time, one of the reasons was that the virus was not common at the time, and only infected hundreds of people each time. In addition, most pharmaceutical companies are reluctant to spend huge sums of money to develop drugs that are mainly for the benefit of poor countries, because people in these countries have no money to buy medicines.
Today, the Ebola epidemic in West Africa is very serious and may pose a threat to other regions, prompting governments and relief organizations to start funding for Ebola vaccines and drugs.
"The Ebola vaccine has never had a huge market, so the big pharmaceutical companies can sell the vaccine to whom? Many times, people," said Ebola expert Gusbert, of the University of Texas Medical School, who helped develop the Ebola vaccine. Wait until the crisis starts and start saying 'OK, we have to do something.'"
Kro, director of the Vaccine Research Center at Vanderbilt University, points out that even if researchers develop drugs that work on animals, they often face the “base of death in biotechnology†because no pharmaceutical company will assist them in completing human trials. Put into production and sales to the market.
Crowe pointed out that it takes millions of dollars to conduct experiments on animals, and it takes hundreds of millions of dollars to conduct human trials and increase production; that is, if new vaccines are to be sold to the market, it is estimated to be between $1 billion and $1.5 billion ( About 1.275 billion to 1.9 billion Singapore dollars). He said: "Who pays for these costs? People invest in a return."
Source: China News Network
Tubular locks is also called tubular lockset, entrance knobset, storeroom knobset, passage knobset, bathroom knob trim, lever knobset, Deadbolt Lock, etc. The tubular locks are commonly found on small gun safes, vending machines and computer locks. It is one common lock. Compared to other similar locks, tubular locks are considered a higher safety product, average pin tumblers and wafer locks.
Lever Lock Set,Door Lever Lock,Door Handle Lever Lock,Handel Lock Lever Handle
ANDJA TRADING PET. LTD. , https://www.lock-cylinder.com